Here at the midpoint, 2012 is looking like a strong year for biotech and some risky names have done quite well. Although not coming close to the gains seen in Arena Pharmaceuticals (ARNA), Amylin Pharmaceuticals (AMLN), or Lexicon Pharmaceuticals (LXRX), RNA interference specialist Alnylam Pharmaceuticals (ALNY) has come on strong with encouraging early-stage data and a greater risk tolerance on the part of investors.
of the standard warnings apply to Alnylam, as the company is indeed
many years from potential product approvals and none of the company's
programs are in advanced trials. Upping the risk even more is the fact
that RNA interference is still an unproven approach and many Big Pharma
companies appear to have backed away from the technology. All that said,
this company has a broad clinical program, numerous high-value targets,
deep IP, and a healthy balance sheet.
Read the full article here:
Alnylam Far From Primetime, But Still An Intriguing Prospect